GET DAILY SIGNALSAmazon Hires Leading Cardiologist
As Amazon.com, Inc.’s tryst with healthcare seems to strengthen, it has now reportedly welcomed one of the leading cardiologists in the U.S. into its team.
Maulik Majmudar, associate director of the Healthcare Transformation Lab at Massachusetts General Hospital, posted on Twitter that he is moving to "an exciting and challenging role @amazon."
Amazon’s ‘healthcare plans’ were already apparent after it acquired online pharma delivery platform PillPack in June, which followed earlier reports of the e-commerce giant’s collaboration with Berkshire Hathaway and JP Morgan & Chase on a project for lowering medical costs of companies and their employees. The firm is also selling medical supplies to doctors, dentists, and hospitals.
Majmudar, who has long been associated with technological innovation in healthcare, mentioned in his tweet that he hopes the opportunity to work with Amazon to lead to “a truly meaningful impact on the health and well-being of hundreds of millions of individuals throughout the world,"
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
JPM sees its Stochastic Oscillator recovers from oversold territory
On October 07, 2026, the Stochastic Oscillator for JPM moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 54 instances where the indicator left the oversold zone. In 35 of the 54 cases the stock moved higher in the following days. This puts the odds of a move higher at over 65%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where JPM's RSI Oscillator exited the oversold zone, 17 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 61%.
The Moving Average Convergence Divergence (MACD) for JPM just turned positive on October 12, 2026. Looking at past instances where JPM's MACD turned positive, the stock continued to rise in 26 of 48 cases over the following month. The odds of a continued upward trend are 54%.
Following a +2.32% 3-day Advance, the price is estimated to grow further. Considering data from situations where JPM advanced for three days, in 217 of 364 cases, the price rose further within the following month. The odds of a continued upward trend are 60%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on JPM as a result. In 43 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 52%.
JPM moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
JPM broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for JPM entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 1 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 9 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 22, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating steady price growth. JPM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 53 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: JPM's P/B Ratio (2.534) is slightly higher than the industry average of (1.492). P/E Ratio (14.416) is within average values for comparable stocks, (11.617). Projected Growth (PEG Ratio) (1.562) is also within normal values, averaging (2.139). Dividend Yield (0.020) settles around the average of (0.035) among similar stocks. P/S Ratio (4.888) is also within normal values, averaging (3.867).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a major bank
Industry MajorBanks
Advertisement